Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

Mental Health

25th Feb 2026

Treating agitation with brexpiprazole in different Alzheimer’s dementia patient subgroups: a plain language summary

25th Feb 2026

Side-effect profile of brexpiprazole for agitation in people with Alzheimer’s dementia: a plain language summary

25th Feb 2026

Plain language summary: Focusing on life engagement as a treatment aim for adults experiencing major depressive disorder

22nd Jan 2026

Plain language summary: Pimavanserin versus other atypical antipsychotics for falls and fractures in long-term care patients with Parkinson’s disease psychosis

28th Nov 2025

Expert guidance on early bipolar I treatment: plain language summary

28th Nov 2025

Plain language summary of aripiprazole injection timing in people with schizophrenia

13th Mar 2025

Plain language summary of mortality rates in patients with Parkinson’s disease psychosis treated with pimavanserin or other atypical antipsychotics

11th Feb 2025

Plain language summary: Investigating the new GlyT1 inhibitor iclepertin (BI 425809) for treating cognitive symptoms in schizophrenia

22nd Jul 2022

Plain language summary of the effects of iclepertin (BI 425809) on cognition in patients with schizophrenia

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy